Hossein Borghaei, DO, MS: As far as PD-L1 testing, I’m pretty sure I know how it is at your center because we have very similar systems. But that’s much simpler testing. That’s immunohistochemistry ...

NORTHFIELD, Ill.--(BUSINESS WIRE)--The College of American Pathologists (CAP) in collaboration with the International Association for the Study of Lung Cancer (IASLC), Pulmonary Pathology Society (PPS ...

NORTHFIELD, Ill.--(BUSINESS WIRE)--The College of American Pathologists (CAP), in collaboration with five other societies, developed a draft evidence-based clinical practice guideline that aims to ...

Biomarker testing has become “increasingly critical” in the care of non-small cell lung cancer.A new investigation into testing rates proved “reassuring” to Kenneth L. Kehl, MD, MPH, assistant ...

Mortality within 30 days of receiving checkpoint inhibitor immunotherapy: An Australian multicenter review. % of LA pts I ordered the test 74 31.2 50, 100 % of LA pts another ONC ordered the test 11 ...

The College of American Pathologists (CAP), in collaboration with five other societies, developed a draft evidence-based clinical practice guideline that aims to optimize PD-L1 testing for patients ...

Jonathan Thompson, MD, MS, emphasized that comprehensive biomarker testing with next-generation sequencing and PD-L1 analysis—implemented as reflex testing at biopsy—is essential to guide precision ...

The study suggests standardized uptake values may be a useful marker to predict treatment response and prognosis in lung adenocarcinoma. Maximum standardized uptake value (SUVmax) in lung ...

The new Phase III study will test calderasib in a chemo-free regimen for G12C-mutated patients regardless of PD-L1 status.

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...